Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)
Using repeated arthroscopic biopsies of patients with rheumatoid arthritis, the researchers will assess changes in the immune response that occur as a result of treatment with rituximab.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Assessment of the Immunomodulatory Effects of Rituximab in Seropositive Rheumatoid Arthritis Using Arthroscopic Synovial Biopsies|
- American College of Rheumatology (ACR) 20 at Week 12 [ Time Frame: 0 and 12 weeks ] [ Designated as safety issue: No ]ACR 20, the American College of Rheumatology (ACR) definition of 20% improvement is based on a 20% improvement (compared to baseline values) in tender and swollen joint counts and 20% improvement in 3 of the remaining 5 core set measures (subject global assessment of pain, subject global assessment of disease activity, physician global assessment of disease activity, subject assessment of physical function) and one acute phase reactant value (CRP).
|Study Start Date:||June 2008|
|Study Completion Date:||December 2009|
|Primary Completion Date:||December 2009 (Final data collection date for primary outcome measure)|
all patients get treatment
treatment with rituximab
Other Name: rituxan
Using repeated arthroscopic biopsies of patients with rheumatoid arthritis, the researchers will assess changes in the immune response that occur after treatment with rituximab.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00147966
|United States, California|
|La Jolla, California, United States, 92093|
|Principal Investigator:||Arthur Kavanaugh, MD||UCSD CIT|